Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Berenberg Conference 2015
17 slides from Novo Nordisk A/s Class B's conference presentation, Dec 1, 2015
Slide 1: Investor presentation Berenberg Conference
Slide 1 Investor presentation Berenberg Conference 1 December 2015 Mexico City – part of Cities Changing Diabetes
Slide 2: Forward-looking statements
Investor presentation Berenberg Conference 2015 Slide 2 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2014 and Form 20-F, both filed with the SEC in February
Slide 3: Double-digit diabetes sales growth and strong market leadership
Investor presentation Berenberg Conference 2015 Slide 3 Novo Nordisk has generated double-digit diabetes sales growth and holds a strong diabetes market leadership Reported annual diabetes care sales Global diabetes care value market share DKK Insulin GLP-1 Other diabetes care Novo Nordisk Sanofi Me
Slide 4: North America is the main contributor to growth
Investor presentation Berenberg Conference 2015 Slide 4 North America is the main contributor to growth Sales as reported – First nine months of 2015 Growth analysis – First nine months of 2015 Japan & Korea Local currencies Growth Share of growth Region China +10% North America 10% 56% +26% 5% 10%
Slide 5: Growth is driven by Victoza and modern insulin
Investor presentation Berenberg Conference 2015 Slide 5 Growth is driven by Victoza® and modern insulin Sales as reported – First nine months of 2015 Growth analysis – First nine months of 2015 Other biopharmaceuticals Local currencies Growth Share of growth Norditropin® +31% New-generation insulin
Slide 6: Victoza maintains leadership in the faster growing US GLP-1 market
Investor presentation Berenberg Conference 2015 Slide 6 Victoza® maintains leadership in the faster growing US GLP-1 market US GLP-1 market development US GLP-1 market shares MAT GLP-1 Growth rate Total TRx MAT volume GLP-1 TRx Victoza® exenatide TRx (000) growth rate market share albiglutide dulagl
Slide 7: North America drives strong Levemir growth despite increased competition
Investor presentation Berenberg Conference 2015 Slide 7 North America drives strong Levemir® growth despite increased competition Levemir® sales growth driven by strong Levemir® gains US market share performance in North America despite introduction of glargine U300 DKK Growth in local currency Leve
Slide 8: Roll-out of degludec portfolio is progressing
Investor presentation Berenberg Conference 2015 Slide 8 Roll-out of degludec portfolio is progressing Tresiba® value share of basal insulin segment Key launch observations in selected countries Switzerland India United Kingdom • Tresiba® launched in 36 countries Japan Sweden Germany • Tresiba® has s
Slide 9: Tresiba has distinctly different product features than competitor basal insulins
Investor presentation Berenberg Conference 2015 Slide 9 Tresiba® has distinctly different product features than competitor basal insulins glargine U100 glargine U300 Duration of action1 • At least 42 hours2 • Up to 24 hours3 • Up to 36 hours4 • Once daily at any time of day5 • Once daily at any time
Slide 10: Encouraging early prescription development for Saxenda
Investor presentation Berenberg Conference 2015 Slide 10 Encouraging early prescription development for Saxenda® Prescription volume uptake of anti-obesity medications recently launched in the US Key launch observations TRx naltrexone HCI & bupropion HCI lorcaserin • Encouraging Saxenda® uptake cont
Slide 11: Semaglutide shows strong efficacy across treatment cascade
Investor presentation Berenberg Conference 2015 Slide 11 In phase 3 trials semaglutide shows strong efficacy across treatment cascade with potential as best in-class GLP-1 Comparison of HbA1c and weight lowering effect in SUSTAIN 1, 3 and 4 trials % patients HbA1c ≤7% Semaglutide 1 mg Semaglutide 0.
Slide 12: Oral semaglutide reduced HbA1c and body weight in phase 2 trial
Investor presentation Berenberg Conference 2015 Slide 12 Oral semaglutide dose dependently reduced HbA1c and body weight in a 26-week phase 2 trial in type 2 diabetes HbA1c reduction from a mean baseline of 7.9% Weight loss from a mean base line of 92 kg Placebo Sema 2.5 mg Sema 5 mg Sema 10 mg Sema
Slide 13: Strong R&D newsflow expected to continue in 2016 and beyond
Investor presentation Berenberg Conference 2015 Slide 13 Strong R&D newsflow expected to continue in 2016 and beyond Project Before end H1 2016 H2 2016 2017 2018 Faster-acting insulin aspart US & EU submission Tresiba® SWITCH results DEVOTE results Victoza® LEADER results Semaglutide – QW GLP-1 Phas
Slide 14: Financial outlook for 2015
Investor presentation Berenberg Conference 2015 Slide 14 Financial outlook for 2015 Expectations Previous expectations 29 October 2015 6 August 2015 Sales growth - local currencies 7-9% 7-9% Sales growth - reported Around 13 percentage points higher Around 14 percentage points higher Operating profi
Slide 15: Upgrade to higher value products expected to continue contributing to growth
Investor presentation Berenberg Conference 2015 Slide 15 Upgrade to higher value products is expected to continue contributing to growth Components of insulin sales growth Composition of product mix growth Market growth Market share Price Mix Sales growth 10% Continued conversion from vial/syringe t
Slide 16: Operating margin leverage limited near term
Investor presentation Berenberg Conference 2015 Slide 16 Operating margin leverage limited near term due to global launch activities and progression of pipeline Gross margin Sales & Distribution Research & Development • The marginal improvements in • Broad portfolio of products to be • Significant i
Slide 17: Investor contact information
Investor presentation First nine months of 2015 Slide 17 Investor contact information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the stock exchange in Novo Nordisk A/S Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on Investor Relations the New Yor